Organ-sparing treatment of kidney cancer in the context of autosomal dominant polycystic kidney disease
https://doi.org/10.17650/1726-9776-2025-21-1-107-111
Abstract
Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease, but the combination of this pathology with renal cell carcinoma is a rare clinical observation. The main treatment method in this situation is nephrectomy. The article presents a clinical case of a 69-year-old patient diagnosed with left kidney cancer pT1bN0M0, stage I with autosomal dominant polycystic kidney disease and chronic kidney disease. Due to severe concomitant kidney pathology, the patient underwent organ-preserving surgery in November of 2024 which included resection of the left kidney with fenestration and excision of renal cysts. The early and late postoperative periods were uneventful with preservation of renal function.
Keywords
autosomal dominant polycystic kidney disease,
clear cell renal cell carcinoma,
organ-sparing treatment
Supporting agencies: The work was performed without external funding
About the Authors
A. M. Pozharytski
N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology
Belarus
Competing Interests:
Belarus
Aliaksandr Mikhailovich Pozharytski - Doctor of the oncourology department of the N.N. Alexandrov RSPC of Oncology and Medical Radiology.
2 Lesnoy Minsk District 223040
Competing Interests:
The authors declare no conflict of interest
A. I. Rolevich
N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology
Belarus
Competing Interests:
Belarus
2 Lesnoy Minsk District 223040
Competing Interests:
The authors declare no conflict of interest
L. N. Suslov
N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology
Belarus
Competing Interests:
Belarus
2 Lesnoy Minsk District 223040
Competing Interests:
The authors declare no conflict of interest
A. N. Ryabcheuski
N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology
Belarus
Competing Interests:
Belarus
2 Lesnoy Minsk District 223040
Competing Interests:
The authors declare no conflict of interest
References
1. Hansen C., Derrick M., Warriach I. et al. The association between autosomal dominant polycystic kidney disease and renal cell carcinoma. Open Journal of Urology. 2021;5:84–90. DOI: 10.4236/oju.2015.56013
2. Bergmann C., Guay-Woodford L., Harris P.C. et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50-58. DOI: 10.1038/s41572-018-0047-y
3. Hajj P., Ferlicot S., Massoud W. et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology. 2009;74(3):631–634. DOI: 10.1016/j.urology.2009.02.078
4. Jilg C.A., Drendel V., Bacher J. et al. Autosomal dominant polycystic kidney disease: prevalence of renal neoplasias in surgical kidney specimens. Nephron Clin Pract. 2013;123:13–21. DOI: 10.1159/000351049
5. Grantham J., Torres V., Chapman A. et al. The importance of total kidney volume in evaluating progression of polycystic kidney disease. N Engl J Med. 2006;354(20):2122–30. DOI: 10.1056/NEJMoa054341
6. Parfrey P.S., Bear J.C., Morgan J. et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med. 2018;323(16):1085-90. DOI: 10.1056/NEJM199010183231601
7. Vias P., Goyal S., Madan R. et al. Renal cell carcinoma in the background of autosomal dominant polycystic kidney disease: report of two cases and review of literature. Indian J Med Paediatr Oncol. 2023:0–5. DOI: 10.1055/s-0043-57268
Review
For citations:
Pozharytski A.M., Rolevich A.I., Suslov L.N., Ryabcheuski A.N. Organ-sparing treatment of kidney cancer in the context of autosomal dominant polycystic kidney disease. Cancer Urology. 2025;21(1):107-111. (In Russ.) https://doi.org/10.17650/1726-9776-2025-21-1-107-111
Views:
99
Email this article 